Achaogen Closes Series B Financing - $26 Million Dollars
Summary
"We have shown that our focus on small molecules that inhibit the emergence of bacterial resistance has a broad market with a clean regulatory path forward, and will present the company with a myriad of compelling strategic opportunities in the future. We are pleased to welcome Domain Venture Partners to our world-class syndicate of life science investors as we begin the next phase of Achaogens growth. "Achaogens science is an ingenious approach to the serious problem of bacterial resistance to antibiotics, and we see great potential for the companys growth in the underserved antibacterial marketplace. Achaogen focuses on high value bacterial targets that are validated, but not yet addressed by safe and effective drugs. For more information about Achaogen please contact John Hollway, Vice President, Business Development at 650-266-1163 or visit www.achaogen.com.